Inverness Counsel’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $681K | Buy |
9,579
+717
| +8% | +$52K | 0.04% | 107 |
|
|
2022
Q2 | $682K | Sell |
8,862
-90
| -1% | -$6.86K | 0.04% | 98 |
|
|
2022
Q1 | $654K | Buy |
8,952
+72
| +0.8% | +$4.83K | 0.03% | 111 |
|
|
2021
Q4 | $554K | Hold |
8,880
| – | – | 0.02% | 111 |
|
|
2021
Q3 | $525K | Sell |
8,880
-375
| -4% | -$24.7K | 0.02% | 118 |
|
|
2021
Q2 | $618K | Sell |
9,255
-325
| -3% | -$21.2K | 0.02% | 108 |
|
|
2021
Q1 | $605K | Buy |
9,580
+650
| +7% | +$40.4K | 0.03% | 99 |
|
|
2020
Q4 | $554K | Hold |
8,930
| – | – | 0.02% | 95 |
|
|
2020
Q3 | $538K | Sell |
8,930
-965
| -10% | -$58.1K | 0.02% | 95 |
|
|
2020
Q2 | $582K | Sell |
9,895
-2,394
| -19% | -$143K | 0.03% | 89 |
|
|
2020
Q1 | $685K | Buy |
12,289
+2,269
| +23% | +$139K | 0.04% | 80 |
|
|
2019
Q4 | $643K | Buy |
10,020
+325
| +3% | +$18.6K | 0.03% | 85 |
|
|
2019
Q3 | $492K | Sell |
9,695
-150
| -2% | -$7.05K | 0.03% | 83 |
|
|
2019
Q2 | $446K | Sell |
9,845
-260
| -3% | -$12.1K | 0.02% | 83 |
|
|
2019
Q1 | $482K | Sell |
10,105
-2,450
| -20% | -$122K | 0.03% | 81 |
|
|
2018
Q4 | $653K | Sell |
12,555
-760
| -6% | -$40.8K | 0.04% | 83 |
|
|
2018
Q3 | $827K | Buy |
13,315
+460
| +4% | +$27.3K | 0.04% | 84 |
|
|
2018
Q2 | $711K | Sell |
12,855
-569
| -4% | -$30.7K | 0.04% | 86 |
|
|
2018
Q1 | $849K | Buy |
13,424
+2,459
| +22% | +$158K | 0.05% | 90 |
|
|
2017
Q4 | $672K | Sell |
10,965
-800
| -7% | -$50K | 0.04% | 75 |
|
|
2017
Q3 | $750K | Buy |
11,765
+200
| +2% | +$11.7K | 0.05% | 75 |
|
|
2017
Q2 | $644K | Sell |
11,565
-400
| -3% | -$21.8K | 0.04% | 73 |
|
|
2017
Q1 | $634K | Sell |
11,965
-40
| -0.3% | -$2.19K | 0.04% | 75 |
|
|
2016
Q4 | $592K | Sell |
12,005
-4,257
| -26% | -$233K | 0.04% | 73 |
|
|
2016
Q3 | $877K | Sell |
16,262
-1,460
| -8% | -$93.8K | 0.07% | 67 |
|
|
2016
Q2 | $1.3M | Buy |
17,722
+227
| +1% | +$16K | 0.1% | 63 |
|
|
2016
Q1 | $1.12M | Sell |
17,495
-455
| -3% | -$28.7K | 0.09% | 60 |
|
|
2015
Q4 | $1.24M | Sell |
17,950
-5,895
| -25% | -$390K | 0.09% | 62 |
|
|
2015
Q3 | $1.41M | Buy |
23,845
+175
| +0.7% | +$11.1K | 0.12% | 61 |
|
|
2015
Q2 | $1.57M | Sell |
23,670
-1,170
| -5% | -$77.1K | 0.11% | 65 |
|
|
2015
Q1 | $1.6M | Buy |
24,840
+640
| +3% | +$40.1K | 0.12% | 65 |
|
|
2014
Q4 | $1.43M | Sell |
24,200
-275
| -1% | -$15.5K | 0.11% | 65 |
|
|
2014
Q3 | $1.25M | Buy |
24,475
+3,562
| +17% | +$178K | 0.1% | 67 |
|
|
2014
Q2 | $1.01M | Buy |
20,913
+5,293
| +34% | +$261K | 0.08% | 72 |
|
|
2014
Q1 | $811K | Sell |
15,620
-25
| -0.2% | -$1.33K | 0.06% | 76 |
|
|
2013
Q4 | $832K | Hold |
15,645
| – | – | 0.07% | 79 |
|
|
2013
Q3 | $724K | Sell |
15,645
-150
| -0.9% | -$6.58K | 0.06% | 78 |
|
|
2013
Q2 | $706K | Buy |
+15,795
| New | +$686K | 0.06% | 73 |
|
Other funds holding BMY
Inverness Counsel's BMY Position: Q3 2022 in Review
Inverness Counsel increased its Bristol-Myers Squibb (BMY) stake by 8.1% in Q3 2022, buying an estimated $52K and bringing the position to 9,579 shares worth $681K. The position accounts for 0.04% of the portfolio, ranked #107.
Inverness Counsel first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.6M in Q1 2015. 2,471 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- Inverness Counsel held 9,579 shares of Bristol-Myers Squibb worth $681K as of Q3 2022.
- Inverness Counsel bought 717 Bristol-Myers Squibb shares in Q3 2022, an estimated $52K.
- Bristol-Myers Squibb made up 0.04% of Inverness Counsel's portfolio in Q3 2022, its #107 holding.
- Inverness Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- Inverness Counsel's Bristol-Myers Squibb position peaked at $1.6M in Q1 2015.
- 2,471 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.